Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS

Launched by AZIENDA DI SERVIZI ALLA PERSONA DI PAVIA · May 16, 2024

Keywords

ClinConnect Summary

This study aims to evaluate the efficacy and safety of lecithin-based formulations of Curcuma longa (Meriva™) and Boswellia serrata (Casperome™) extracts in treating gastrointestinal symptoms in patients with post-acute COVID-19 irritable bowel syndrome (PCIBS) and irritable bowel syndrome (IBS) without prior COVID-19 infection. The study was conducted at the Department of Public Health of the University of Pavia, Italy. Participants included 16 PCIBS patients and 28 IBS controls, aged 18-75 years. They were administered 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts twice...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18-75 years, male or female.
• • Diagnosis of post-acute COVID-19 irritable bowel syndrome (PCIBS) 60-120 days after the end of infection.
• • Diagnosis of irritable bowel syndrome (IBS) without prior COVID-19 infection.
• • Evidence of functional abdominal bloating/distention (FAB/D) type of IBS according to Mearin et al.
• • Presence of enteral dysbiosis defined by increased urinary indican values with normal skatole urinary concentration.
• Exclusion Criteria:
• • Normal urinary indican values or increased urinary skatole values.
• • Subjects already on a low FODMAP diet or other dietary restrictions such as gluten-free diet or lactose-free diet within the past 6 months.
• • Allergies to soy, nuts, or seafood, or insulin-dependent diabetes.
• • Known history of celiac disease, symptomatic diverticular disease, inflammatory bowel disease, or microscopic colitis.
• • Prior small bowel or colonic surgery or cholecystectomy.
• • Presence of bloody diarrhea or severe vomiting.
• • Severe renal disease (serum creatinine \>1.5 mg/dL) or liver disease (altered liver function tests).

Trial Officials